Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ECOR vs COCP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

COCP Captures Overall Composite Edge (45.4 HOLD vs 56.8 HOLD), While ECOR Leads 4–0 on Growth & Valuation Pillars

COCP Overall Winner 6-Pillar Tally: ECOR 4 – 0 COCP (2 Tie) Matrix Metrics: ECOR 3 – 5 COCP

As of Nov 19, 2026, Cocrystal Pharma, Inc. (COCP) captures the overall head-to-head institutional edge over electroCore, Inc. (ECOR) on higher Unified Composite conviction (45.4/100 HOLD vs. 56.8/100 HOLD) after splitting the core matrix 5–3 (led by composite factor balance), while ECOR wins 4–0 across the 6-pillar growth and valuation breakdown. ECOR trades at $4.85 (N/M Forward P/E, -33.1% operating margin) versus COCP at $0.97 (N/M Forward P/E, -2646.0% operating margin).

  • Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. COCP 45.4/100 HOLD), COCP captures the overall institutional head-to-head verdict (5–3 matrix metrics and 0–4 across the 6 pillars) due to superior fundamental profitability (-2646.0% vs. -33.1% operating margin) and revenue trajectory (+26.9% vs. +11.5% YoY).
  • Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile COCP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECOR vs COCP
ECOR NASDAQ
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67
COCP NASDAQ Head-to-Head Winner
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$0.97
-0.72% 1D
Market Cap $18.5M
TTM Revenue $435,000
Forward P/E N/M
Beta / 30D Vol 1.01β · 55% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 44.0 Fund 50.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.8%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $1.01 · SMA50: $1.06

6-Pillar Scorecard Institutional Category Breakdown (ECOR 4 – 0 COCP)

Columns: Metric · ECOR · COCP
1. Valuation Multiples ECOR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x 35.0x
2. Growth & Scale ECOR
Revenue Growth (YoY) +11.5% +26.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $38M $435,000
Market Cap $47.7M $18.5M
3. Profitability & Quality ECOR
Gross Margin 87.7% N/A
Operating Margin -33.1% -2646.0%
Net Profit Margin -33.5% 0.0%
Return on Equity (ROE) -478.7% -219.1%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$6.9M -$7.6M
Cash Flow Margin -18.1% N/A
Net Cash / Leverage $4.6M Net Debt $3.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECOR (3) vs COCP (5)
Institutional Metric ECOR COCP Criterion Row Edge
Market Capitalization
Scale
$47.7M $18.5M Larger Scale ECOR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+11.5% +26.9% Higher Growth COCP
Operating Margin (TTM)
Profitability
-33.1% -2646.0% Higher Margin ECOR
Net Profit Margin
Profitability
-33.5% 0.0% Higher Margin COCP
Return on Equity (ROE)
Capital Efficiency
-478.7% -219.1% Higher ROE COCP
52-Week Range Position
Momentum
6% ($4–$13) 16% ($1–$2) Stronger Trend COCP
Beta / 30D Volatility
Risk Regime
1.52β · 155% Vol 1.01β · 55% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
56.8 / 100 (HOLD) 45.4 / 100 (HOLD) Higher Composite ECOR
Trailing 12M Revenue (USD)
Operating Scale
$38M $435,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · 35.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.9M ($4.6M Net Debt) -$7.6M ($3.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +36.8 pp
ECOR: -34.01% · COCP: +2.79%
3M Horizon COCP +38.24 pp
ECOR: -53.9% · COCP: -15.66%
6M Horizon COCP +4.86 pp
ECOR: -19.03% · COCP: -14.17%
1Y Horizon ECOR +0.95 pp
ECOR: -3.96% · COCP: -4.91%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ECOR Revenue COCP Revenue ECOR Op. Margin COCP Op. Margin Margin Leader
FY2018 $0M N/A -5494.1% N/A ECOR
FY2019 $0M $10M -1928.2% -737.4% COCP
FY2020 $0M $0M -707.9% -476.0% COCP
FY2021 $10M N/A -367.7% N/A ECOR
FY2022 $10M N/A -266.2% N/A ECOR
FY2023 $20M N/A -120.2% N/A ECOR
FY2024 $30M N/A -48.3% N/A ECOR
FY2025 $30M N/A -41.1% N/A ECOR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $18.5M market capitalization and -2646.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ECOR vs COCP Key Questions & Quantitative Answers

As of Nov 19, 2026, Cocrystal Pharma, Inc. (COCP) captures the overall head-to-head institutional edge over electroCore, Inc. (ECOR) on higher Unified Composite conviction (45.4/100 HOLD vs. 56.8/100 HOLD) after splitting the core matrix 5–3 (led by composite factor balance), while ECOR wins 4–0 across the 6-pillar growth and valuation breakdown. ECOR trades at $4.85 (N/M Forward P/E, -33.1% operating margin) versus COCP at $0.97 (N/M Forward P/E, -2646.0% operating margin). Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. COCP 45.4/100 HOLD), COCP captures the overall institutional head-to-head verdict (5–3 matrix metrics and 0–4 across the 6 pillars) due to superior fundamental profitability (-2646.0% vs. -33.1% operating margin) and revenue trajectory (+26.9% vs. +11.5% YoY). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile COCP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECOR leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $435,000 TTM revenue (N/A gross margin, -2646.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECOR cumulative revenue shifted +200.0% while COCP shifted N/A. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.

ECOR screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 35.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus COCP (-219.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.01β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.